The Next Glivec? Merck Sues Glenmark In Bid To Protect Januvia From Indian Generics
This article was originally published in PharmAsia News
Glenmark’s move to sell generics of Januvia and Janumet is being legally challenged by Merck and Sun Pharma, with Section 3 (d) of the Indian Patent Act likely to play a critical role in determining who wins and who loses. Is a Glivec-like battle shaping up?
You may also be interested in...
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.